In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer

Journal of Controlled Release

Volumn 157, Issue 2, 2012, Pages 190-195

  Kim, Cha Eun ^a   Lim, Sun Kyung ^a   Kim, Jin Seok ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

cromolyn; gemcitabine; pancreatic cancer; PEGylated liposome

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTIPROLIFERATIVE EFFECT; ANTITUMOR EFFECT; CROMOLYN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYL PHOSPHATIDYLCHOLINE; GEMCITABINE; IN-VITRO; IN-VIVO; LIPOSOMAL FORMULATION; METHOXY; NUDE MICE; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; PEGYLATED LIPOSOMES; STABILITY STUDY; TARGET PROTEINS;

CELLS; DISEASES; LIPOSOMES; PHOSPHOLIPIDS; PROTEINS; TUMORS;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; CROMOGLYCATE DISODIUM; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; PEGYLATED LIPOSOMAL CROMOLYN; PROTEIN S 100; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CROMOLYN SODIUM; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855776494     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.066     Document Type: Article

References (27)

1. K. Pliarchopoulou, and D. Pectasides Pancreatic cancer: current and future treatment strategies Cancer Treat. Rev. 35 2009 431 436
2. Y. Yokoyama, Y. Nimura, and M. Nagino Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies Surg. Today 39 2009 466 475
3. M. Wagner, N. Dikopoulos, C. Kulli, H. Friess, and M.W. Buchler Standard surgical treatment in pancreatic cancer Ann. Oncol. 10 Suppl. 4 1999 247 251
4. J. Nieto, M.L. Grossbard, and P. Kozuch Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13 2008 562 576 (Pubitemid 351872873)
5. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413 (Pubitemid 27251144)
6. R. Donato Intracellular and extracellular roles of S100 proteins Microsc. Res. Tech. 60 2003 540 551
7. L.J. Sparvero, D. Asafu-Adjei, R. Kang, D. Tang, N. Amin, J. Im, R. Rutledge, B. Lin, A.A. Amoscato, H.J. Zeh, and M.T. Lotze RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation J. Transl. Med. 7 2009 17
8. T. Arumugam, D.M. Simeone, A.M. Schmidt, and C.D. Logsdon S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE) J. Biol. Chem. 279 2004 5059 5065 (Pubitemid 38220521)
9. A.M. Avunduk, M.C. Avunduk, Z. Kapicioglu, N. Akyol, and L. Tavli Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis Ophthalmology 107 2000 1333 1337
10. A.A. Hemmati, Z. Nazari, M.E. Motlagh, and S. Goldasteh The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat Pharmacol. Res. 46 2002 229 234 (Pubitemid 35300761)
11. T. Shishibori, Y. Oyama, O. Matsushita, K. Yamashita, H. Furuichi, A. Okabe, H. Maeta, Y. Hata, and R. Kobayashi Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family Biochem. J. 338 Pt 3 1999 583 589 (Pubitemid 29140060)
12. M. Okada, H. Tokumitsu, Y. Kubota, and R. Kobayashi Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein Biochem. Biophys. Res. Commun. 292 2002 1023 1030 (Pubitemid 34687307)
13. T. Arumugam, V. Ramachandran, and C.D. Logsdon Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models J. Natl. Cancer Inst. 98 2006 1806 1818 (Pubitemid 46017932)
14. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160 (Pubitemid 40282557)
15. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, C. Redemann, and F.J. Martin Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464 (Pubitemid 21916061)
16. Y.H. Bae, and K. Park Targeted drug delivery to tumors: Myths, reality and possibility J. Control. Release 153 2011 198 205
17. S.D. Li, and L. Huang Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting J. Control. Release 145 2010 178 181
18. N. Sato, N. Fukushima, H. Matsubayashi, and M. Goggins Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling Oncogene 23 2004 1531 1538 (Pubitemid 38406515)
19. T. Namba, T. Homan, T. Nishimura, S. Mima, T. Hoshino, and T. Mizushima Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects J. Biol. Chem. 284 2009 4158 4167
20. T. Crnogorac-Jurcevic, E. Missiaglia, E. Blaveri, R. Gangeswaran, M. Jones, B. Terris, E. Costello, J.P. Neoptolemos, and N.R. Lemoine Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent J. Pathol. 201 2003 63 74 (Pubitemid 37121204)
21. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, and G.Z. Zhu Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time FEBS Lett. 386 1996 243 246 (Pubitemid 26173078)
22. P.J. Photos, L. Bacakova, B. Discher, F.S. Bates, and D.E. Discher Polymer vesicles in vivo: correlations with PEG molecular weight J. Control. Release 90 2003 323 334 (Pubitemid 36859964)
23. M. Silvander, M. Johnsson, and K. Edwards Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum Chem. Phys. Lipids 97 1998 15 26 (Pubitemid 28557010)
24. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
25. H. Maeda, T. Sawa, and T. Konno Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control. Release 74 2001 47 61 (Pubitemid 32727608)
26. W. Wang, J.L. Abbruzzese, D.B. Evans, L. Larry, K.R. Cleary, and P.J. Chiao The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin. Cancer Res. 5 1999 119 127 (Pubitemid 29045184)
27. A.S. Baldwin Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB J. Clin. Invest. 107 2001 241 246 (Pubitemid 32157954)